## **SENATE BILL NO. 397**

June 11, 2025, Introduced by Senators HERTEL and SANTANA and referred to Committee on Health Policy.

A bill to amend 1939 PA 280, entitled "The social welfare act,"

by amending section 109h (MCL 400.109h), as amended by 2022 PA 19.

## THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1 Sec. 109h. (1) If the department develops a prior
- 2 authorization process for prescription drugs as part of the
- 3 pharmaceutical services offered under the medical assistance
- 4 program administered under this act, the department shall not
- 5 require prior authorization for the following single source brand

- name, generic equivalent of a multiple source brand name, or other
  prescription drugs:
- 3 (a) A central nervous system prescription drug that is
  4 classified as an anticonvulsant, antidepressant, antipsychotic, or
  5 a noncontrolled substance antianxiety drug in a generally accepted
  6 standard medical reference.
  - (b) A prescription drug that is cross-indicated for a central nervous system drug exempted under subdivision (a) as documented in a generally accepted standard medical reference.
- 10 (c) Unless the prescription drug is a controlled substance or 11 the prescription drug is being prescribed to treat a condition that is excluded from coverage under this act, a prescription drug that 12 is recognized in a generally accepted standard medical reference as 13 14 effective in the treatment of conditions specified in the most 15 recent diagnostic and statistical manual of mental disorders 16 published by the American Psychiatric Association, including 17 substance use disorder. The department or the department's agent 18 shall not deny a request for prior authorization of a controlled substance under this subdivision unless the department or the 19 20 department's agent determines that the controlled substance or the dosage of the controlled substance being prescribed is not 21 22 consistent with its licensed indications or with generally accepted 23 medical practice as documented in a standard medical reference.
  - (d) A prescription drug that is recognized in a generally accepted standard medical reference to prevent acquisition of or to treat human immunodeficiency virus infection or complication of the human immunodeficiency virus or acquired immunodeficiency syndrome.
- (e) A prescription drug that is recognized in a generallyaccepted standard medical reference for the treatment of and is

7

8

9

24

25

2627

- 1 being prescribed to a patient for the treatment of any of the
- 2 following:
- (i) Cancer.
- 4 (ii) Organ replacement therapy.
- 5 (iii) Epilepsy or seizure disorder.
- 6 (iv) Opioid withdrawal symptom management or opioid use
- 7 disorder, including, but not limited to, buprenorphine/naloxone
- 8 tablets that are more than 32 milligrams.
- 9 (2) This section applies to drugs being provided under a
- 10 contract between the department and a health maintenance
- 11 organization.
- 12 (3) This section does not prohibit the department from
- 13 contracting with a managed care organization for pharmaceutical
- 14 services offered under the medical assistance program administered
- 15 under this act as long as the contract complies with the provisions
- 16 of this section.
- 17 (4) As used in this section:
- 18 (a) "Controlled substance" means that term as defined in
- 19 section 7104 of the public health code, 1978 PA 368, MCL 333.7104.
- 20 (b) "Cross-indicated" means a drug that is used for a purpose
- 21 generally held to be reasonable, appropriate, and within community
- 22 standards of practice even though the use is not included in the
- 23 United States Food and Drug Administration's approved labeled
- 24 indications for that drug.
- 25 (c) "Prescriber" means that term as defined in section 17708
- 26 of the public health code, 1978 PA 368, MCL 333.17708.
- 27 (d) "Prescription" or "prescription drug" means that term as
- 28 defined in section 17708 of the public health code, 1978 PA 368,
- **29** MCL 333.17708.

1	(e) "Prior authorization" means a process implemented by the
2	department that conditions, delays, or denies the delivery of
3	particular pharmaceutical services to Medicaid beneficiaries upon
4	application of predetermined criteria by the department or the
5	department's agent for those pharmaceutical services covered by the
6	department on a fee-for-service basis or according to a contract
7	for those services. The process may require a prescriber to verify
8	with the department or the department's agent that the proposed
9	medical use of a prescription drug being prescribed for a patient
10	meets the predetermined criteria for a prescription drug that is
11	otherwise covered under this act or require a prescriber to obtain
12	authorization from the department or the department's agent before
13	prescribing or dispensing a prescription drug that is not included
14	on a preferred drug list or that is subject to special access or
15	reimbursement restrictions.